Intech Investment Management LLC Has $3.85 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Intech Investment Management LLC grew its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 370.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,221 shares of the specialty pharmaceutical company's stock after acquiring an additional 24,582 shares during the quarter. Intech Investment Management LLC owned about 0.05% of Jazz Pharmaceuticals worth $3,845,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $25,000. Jones Financial Companies Lllp raised its stake in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the period. UMB Bank n.a. lifted its holdings in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after acquiring an additional 129 shares in the last quarter. Lindbrook Capital LLC boosted its position in Jazz Pharmaceuticals by 82.6% during the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock worth $48,000 after purchasing an additional 176 shares during the period. Finally, Itau Unibanco Holding S.A. increased its holdings in Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock valued at $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 2.3 %

Shares of JAZZ traded up $3.26 during trading hours on Monday, hitting $142.02. 969,027 shares of the company were exchanged, compared to its average volume of 705,011. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market cap of $8.63 billion, a PE ratio of 20.00, a PEG ratio of 1.04 and a beta of 0.44. The firm's 50 day moving average is $131.41 and its 200-day moving average is $121.79. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $148.06.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 7,080 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares of the company's stock, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,140 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares of the company's stock, valued at approximately $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock worth $4,022,825 over the last ninety days. Company insiders own 4.20% of the company's stock.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several analyst reports. Piper Sandler reaffirmed an "overweight" rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Truist Financial boosted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $183.00 price objective (up previously from $175.00) on shares of Jazz Pharmaceuticals in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.